UK begins review of Palantir’s NHS data analytics contract, raising questions about continuation

Britain has launched a review of its National Health Service contract with U.S. data analytics firm Palantir, a move that could determine whether the government continues the partnership or ends it early. Multiple outlets reported that the review is being carried out amid political scrutiny and calls for the government to test contractual exit options, including the use of a break clause.

The contract in question has been described in reporting as a multi-year, roughly £330 million NHS deal. A separate figure circulating in coverage puts the arrangement at about $445 million, suggesting that reported totals may vary depending on how the scope is counted.

Beyond the contract value, the review appears to be driven by pressure from within the UK political system and civil-society groups. Commentary in the coverage points to concerns that have ranged from data privacy and public oversight to whether Palantir’s software should be used across healthcare operations.

Amnesty International also weighed into the debate earlier this year, saying health and human-rights groups urged hospitals not to use Palantir software and asked NHS England to cancel the contract entirely. That campaign adds to the broader risk of regulatory, reputational, and compliance friction if the review process turns adversarial.

On the policy side, Computing UK reported that a senior MP rejected the idea that criticism of Palantir’s multimillion-pound NHS contract was purely ideological, implying that lawmakers see the scrutiny as grounded in governance and accountability issues. The same reporting stream indicates that the government’s right to review the agreement is now central to the dispute.

Palantir, for its part, did not disclose additional details in the public coverage that this news brief reflects, including what specific performance, cost, or compliance findings have triggered the current review, nor what negotiating position it is taking with the NHS or the UK government.

For Palantir and the UK technology market, the episode highlights how data-infrastructure contracts in public services increasingly face political review, especially when contracts touch sensitive personal information and high-visibility public services like healthcare. Even when deals are technically delivered, governments may reassess long-term lock-in, procurement value, and oversight mechanisms.

What to watch next is whether the review results in an extension, renegotiated terms, or a termination that could force changes in how NHS organizations rely on Palantir-linked systems. Also important will be any disclosure about whether the break clause is being actively pursued, and whether ministers and regulators will publish the review’s findings or summaries for parliamentary or public scrutiny.